About Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -0.19$ per share.

The book value per share is 0.06$

Nymox Pharmaceutical Corp. website

Create a solid portfolio with NYMX

Add NYMX to your portfolio and optimize it!


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- 60.00% -11M - -11M -0.19 - - 58M 0.06 -7M - -7M